| CTSS — Cathepsin S | |
|---|---|
| Symbol | CTSS |
| Full Name | Cathepsin S |
| Chromosome | 1q21.3 |
| NCBI Gene | 1520 |
| Ensembl | ENSG00000163131 |
| OMIM | 600565 |
| UniProt | P07237 |
| Diseases | [Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [Multiple Sclerosis](/diseases/ms) |
| Expression | [Microglia](/cell-types/microglia-neuroinflammation), Macrophages, Dendritic cells |
CTSS (Cathepsin S) encodes a lysosomal cysteine protease that has emerged as a critical player in both immune function and neurodegenerative disease pathogenesis. Located on chromosome 1q21.3, cathepsin S is unique among cathepsins for its ability to maintain proteolytic activity at neutral pH and be secreted extracellularly, making it particularly relevant to inflammatory processes in the brain[@yuan2021][@yang2020].
The gene encodes a protein of 331 amino acids that is primarily expressed in professional antigen-presenting cells including microglia, macrophages, and dendritic cells. Cathepsin S plays essential roles in antigen processing, extracellular matrix remodeling, and more recently, has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, and multiple sclerosis[@ma2019][@leyer2017].
The dual nature of cathepsin S—as both a beneficial protease in normal physiology and a potential contributor to pathological processes—makes it a fascinating target for understanding neurodegenerative disease mechanisms.
| Property | Value |
|---|---|
| Gene Symbol | CTSS |
| Full Name | Cathepsin S |
| Chromosomal Location | 1q21.3 |
| NCBI Gene ID | 1520 |
| OMIM ID | 600565 |
| Ensembl ID | ENSG00000163131 |
| UniProt ID | P07237 |
| Protein Length | 331 amino acids |
| Molecular Weight | 37 kDa |
Cathepsin S is synthesized as a preproenzyme requiring multiple processing steps for activation[@Turk2001]:
Cathepsin S employs a cysteine protease mechanism:
| Residue | Role |
|---|---|
| Cys25 | Catalytic cysteine (nucleophile) |
| His159 | Catalytic histidine (base) |
| Asn175 | Oxyanion hole formation |
| Property | Cathepsin S | Other Cathepsins |
|---|---|---|
| Neutral pH activity | Yes | Limited |
| Extracellular secretion | Yes (unique) | Rarely |
| Elastin degradation | High | Variable |
| MHC class II antigen processing | Primary | Partial |
Cathepsin S demonstrates broad substrate specificity[@mack2003]:
In immune cells, cathepsin S is essential for[@riese1998]:
Within the central nervous system, cathepsin S is primarily expressed in[@jenner2018]:
Microglia: High expression in resting and activated microglia
Infiltrating Macrophages: Elevated in neuroinflammatory conditions
Astrocytes: Lower expression than microglia
Cathepsin S has complex and context-dependent roles in AD[@yang2020][@li2020]:
| Function | Mechanism | Evidence |
|---|---|---|
| Aβ degradation | Direct proteolytic cleavage | In vitro studies |
| Plaque clearance | Phagocytosis enhancement | Mouse models |
| Anti-inflammatory | IL-1β processing | Cellular studies |
| Function | Mechanism | Evidence |
|---|---|---|
| Neuroinflammation | Cytokine activation | Human brain studies |
| Blood-brain barrier | ECM degradation | Animal models |
| Synaptic dysfunction | Synaptic protein cleavage | In vitro |
Given its dual role, cathepsin S modulation is complex:
Cathepsin S involvement in PD includes[@ma2019]:
In MS and related conditions[@leyer2017]:
Cathepsin S contributes to chronic pain states[@bevilacqua2016]:
| Region | Expression Level | Cell Types |
|---|---|---|
| Cortex | Moderate | Neurons, glia |
| Hippocampus | High | Microglia, neurons |
| Substantia nigra | Moderate | Microglia, neurons |
| Cerebellum | Low | Granule cells |
| White matter | Variable | Oligodendrocytes |
| Cell Type | Level | Function |
|---|---|---|
| Microglia | High | Antigen presentation, phagocytosis |
| Macrophages | High | Immune surveillance |
| Dendritic cells | Moderate | Antigen processing |
| Astrocytes | Low-Moderate | Metabolic support |
| Neurons | Low | Proteostasis |
| Approach | Rationale | Challenges |
|---|---|---|
| Inhibitors | Reduce neuroinflammation | May impair Aβ clearance |
| Modulators | Fine-tune activity | Specificity |
| Gene therapy | Regulated expression | Delivery |
| Biomarkers | Patient selection | Validation |
Small molecule inhibitors have been developed:
| Method | Application |
|---|---|
| Immunohistochemistry | Tissue localization |
| Activity assays | Fluorogenic substrates |
| Western blot | Protein levels |
| qPCR | mRNA expression |
| RNA-seq | Transcriptome analysis |
| Pathway | Interaction | Effect |
|---|---|---|
| Immune response | Direct role | Antigen processing |
| Extracellular matrix | Substrate | Remodeling |
| Neuroinflammation | Mediator | Cytokine activation |
| Protein aggregation | Modulator | Clearance vs. toxicity |
| Marker | Source | Status |
|---|---|---|
| CTSS activity | CSF | Research |
| CTSS protein | CSF/Plasma | Research |
| CTSS mRNA | Blood | Exploratory |
| Cathepsin | Function in Neurodegeneration |
|---|---|
| CTSB | Aβ degradation, apoptosis |
| CTSD | Aβ degradation, prominent in AD |
| CTSL | Autophagy, synaptic function |
| CTSH | Less characterized |
| CTSS | Immune, inflammation |
Cathepsin S represents a fascinating case study in the complexity of protease biology in neurodegeneration. Its dual role—both promoting beneficial protein clearance and contributing to inflammatory processes—creates challenges for therapeutic targeting. The unique ability of cathepsin S to function at neutral pH and be secreted extracellularly distinguishes it from other lysosomal cathepsins and makes it particularly relevant to neuroinflammatory conditions.
Understanding the context-dependent roles of cathepsin S will be critical for developing effective therapeutic strategies. Cell-type specific approaches that preserve microglial phagocytic function while reducing inflammatory mediator release may provide the best path forward. Additionally, biomarker development could help identify patients most likely to benefit from cathepsin S modulation.
Gene information last updated: 2026-03-28